<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68889">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02004340</url>
  </required_header>
  <id_info>
    <org_study_id>NSFC-81273829</org_study_id>
    <secondary_id>2011CB505201</secondary_id>
    <nct_id>NCT02004340</nct_id>
  </id_info>
  <brief_title>Transcutaneous Auricular Vagus Nerve Stimulation for Pediatric Epilepsy</brief_title>
  <official_title>Transcutaneous Auricular Vagus Nerve Stimulation as a Complementary Treatment for Pediatric Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China  Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>China  Academy of Chinese Medical Sciences</source>
  <oversight_info>
    <authority>China: National Natural Science Foundation</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether transcutaneous auricular vagus nerve
      stimulation as a complementary therapy is effective in the treatment of pediatric epilepsy.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2013</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>frequency of epileptic seizures</measure>
    <time_frame>Change from baseline at 8, 16, 24 weeks respectively in frequency of epileptic seizures</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>participants will be followed for the duration of TVNS intervention, an expected average of 8 weeks&quot;</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Transcutaneous auricular vagal stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transcutaneous stimulation at auricular concha</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transcutaneous auricular non-vagal stimulation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Transcutaneous stimulation at auricular edge</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ear vagus nerve stimulator</intervention_name>
    <arm_group_label>Transcutaneous auricular vagal stimulation</arm_group_label>
    <arm_group_label>Transcutaneous auricular non-vagal stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed as epilepsy;

          -  With age between 2-18 years old;

          -  The number and dose of the medication was kept constant no less than eight weeks
             before intervention;

          -  The patients or their guardians can count the frequency of the seizures and finish
             the study.

        Exclusion Criteria:

          -  The patient is receiving the VNS therapy;

          -  Accompanied with progressive central nervous system diseases;

          -  Have severe heart, liver ,kidney or blood diseases;

          -  Be pregnant or having the schedule of pregnancy in the study period.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 3, 2013</lastchanged_date>
  <firstreceived_date>November 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>China  Academy of Chinese Medical Sciences</investigator_affiliation>
    <investigator_full_name>Wei He</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>pediatric epilepsy</keyword>
  <keyword>transcutaneous vagus nerve stimulation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
